1. Scrip
  2. >>Business

Can Sanofi And GSK Catch Up In mRNA Vaccines?

Pfizer And Moderna Have Head Start

 
• By Andrew McConaghie

GSK and Sanofi have little chance of making a big impact in COVID-19 vaccines, but hope to establish themselves in the technology in key markets such as flu.

GSK vaccines
GSK was the world's biggest vaccine company before SARS-CoV2, but the dazzling success of BioNTech/Pfizer and Moderna's vaccines have changed the landscape forever.

Before SARS-CoV2 struck, GlaxoSmithKline and Sanofi were the world’s two biggest vaccine manufacturers, thanks to their presence across multiple infectious diseases including flu, but the astonishing success of BioNTech/Pfizer and Moderna’s messenger RNA (mRNA)-based COVID-19 jabs has upended that old order.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

GSK Talks Up Nucala COPD Hospitalization Data In Challenge To Dupixent

 
• By Kevin Grogan

As the PDUFA date for the UK major’s IL-5 inhibitor draws close.

Novartis Doubles Down On Push For Higher Drug Prices In Europe

 
• By Jessica Merrill

CEO Vas Narasimhan urged European governments to spend more to support drug innovation during Novartis's first-quarter results call.

Zai’s R&D Head Touts ‘Beauty’ Of Novel Internal Assets

 
• By Dexter Jie Yan

Two potentially first-in-class molecules signify Zai Lab’s renewed drive for the in-house discovery of drugs that it requires “to be innovative, differentiated and to have the potential to make a big difference for patients,” its global R&D head tells Scrip.